Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 11,667.0 | 8,598.0 | 5,199.0 | 12,067.0 | 11,223.0 | 10,060.0 | 8,774.0 | 6,672.3 |
| Revenue growth | 35.7% | 65.4% | -56.9% | 7.5% | 11.6% | 14.7% | 31.5% | 15.8% |
| Cost of goods sold | 1,755.0 | 1,529.0 | 1,811.0 | 2,100.0 | 1,805.0 | 1,757.0 | 1,597.0 | 1,309.6 |
| Gross profit | 9,912.0 | 7,069.0 | 3,388.0 | 9,967.0 | 9,418.0 | 8,303.0 | 7,177.0 | 5,362.8 |
| Gross margin | 85.0% | 82.2% | 65.2% | 82.6% | 83.9% | 82.5% | 81.8% | 80.4% |
| Sales and marketing | 6,100.0 | 4,221.0 | 2,527.0 | 6,060.0 | 5,721.0 | 5,298.0 | 4,367.0 | 3,381.1 |
| Research and development | 1,181.0 | 1,074.0 | 1,068.0 | 1,263.0 | 1,122.0 | 1,387.0 | 1,235.0 | 830.2 |
| General and administrative | 748.0 | 705.0 | 589.0 | 807.0 | 774.0 | 676.0 | 678.0 | 573.9 |
| EBITA | 1,179.0 | 354.0 | -1,535.0 | 1,125.0 | 1,125.0 | 917.0 | 905.0 | 682.1 |
| EBITA margin | 10.1% | 4.1% | -29.5% | 9.3% | 10.0% | 9.1% | 10.3% | 10.2% |
| Amortization of intangibles | 88.0 | 99.0 | 154.0 | 198.0 | 283.0 | 275.0 | 352.0 | 156.5 |
| EBIT | 1,091.0 | 255.0 | -1,689.0 | 927.0 | 842.0 | 642.0 | 553.0 | 525.6 |
| EBIT margin | 9.4% | 3.0% | -32.5% | 7.7% | 7.5% | 6.4% | 6.3% | 7.9% |
| Pre-tax income | 538.0 | -38.0 | -3,151.0 | 775.0 | 485.0 | 417.0 | 277.0 | 926.0 |
| Income taxes | 195.0 | -53.0 | -423.0 | 203.0 | 87.0 | 45.0 | 16.0 | 203.2 |
| Tax rate | 36.2% | 139.5% | 13.4% | 26.2% | 17.9% | 10.8% | 5.8% | 21.9% |
| Net income | 352.0 | -269.0 | -2,687.0 | 565.0 | 406.0 | 378.0 | 282.0 | 764.5 |
| Net margin | 3.0% | -3.1% | -51.7% | 4.7% | 3.6% | 3.8% | 3.2% | 11.5% |
| |
| Diluted EPS | $161,751.00 | ($1.80) | ($19.00) | $3.77 | $2.66 | $2.42 | $1.83 | $5.70 |
| Shares outstanding (diluted) | 0.0 | 149.7 | 141.4 | 149.9 | 152.9 | 156.4 | 154.5 | 134.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|